---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-021099"
form_type: "8-K"
ticker: "CYTK"
cik: "0001061983"
company_name: "CYTOKINETICS INC"
filed_at: "2024-02-27T23:59:59+00:00"
generated_at: "2026-06-05T10:30:36.785083+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Cytokinetics reports Q4 2023 net loss of $1.38/share; positive SEQUOIA-HCM results, NDA planned for Q3 2024

## Summary
- Net loss Q4 2023: $136.9M ($1.38/share); full year net loss $526.2M ($5.45/share).
- Year-end cash $655.4M; additional ~$83M raised via ATM in early 2024; ~2-year cash runway.
- SEQUOIA-HCM showed aficamten improved pVO2 by 1.74 mL/kg/min (p=0.000002) vs placebo; all 10 secondary endpoints met.
- Plans to submit NDA to FDA in Q3 2024 and MAA to EMA in Q4 2024 for aficamten.
- 2024 guidance: revenue $3-5M, operating expenses $420-450M, net cash utilization ~$390-420M.

## SEC filing metadata
- accession: 0000950170-24-021099
- form_type: 8-K
- ticker: CYTK
- cik: 0001061983
- company_name: CYTOKINETICS INC
- filed_at: 2024-02-27T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1061983/000095017024021099/0000950170-24-021099-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1061983/000095017024021099/cytk-20240227.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-021099
- JSON: https://secwatch.observer/filing/0000950170-24-021099.json
- Plain text: https://secwatch.observer/filing/0000950170-24-021099.txt

## Key facts
- Earnings Releases
  CYTOKINETICS INC reported the fourth quarter and full year 2023 results: net income Net loss for the fourth quarter was $136.9 million or $1.38 per share and the net loss for the year 2023 was $526.2 mill.
  - Period: the fourth quarter and full year 2023
  - Net income: Net loss for the fourth quarter was $136.9 million or $1.38 per share and the net loss for the year 2023 was $526.2 mill
  - Result: reported results
  source text: On February 27, 2024, Cytokinetics, Incorporated announced its financial results for the fourth quarter and for the year ended December 31, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1061983/000095017024021099/0000950170-24-021099-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.